van Muijen, Marloes E. http://orcid.org/0000-0001-7934-3329
Atalay, S. http://orcid.org/0000-0002-9671-0386
van Vugt, L. J. http://orcid.org/0000-0001-8788-7211
Vandermaesen, L. M. D. http://orcid.org/0000-0003-0830-6883
van den Reek, J. M. P. A. http://orcid.org/0000-0002-3642-2673
de Jong, E. M. G. J. http://orcid.org/0000-0003-3872-5704
Article History
Accepted: 16 January 2021
First Online: 28 March 2021
Declarations
:
: None.
: ME van Muijen carries out clinical trials for Abbvie, Celgene, Janssen and Novartis, and has received a speaker’s fee from Janssen. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Centre Nijmegen, The Netherlands. S Atalay has received grants from Janssen, Abbvie, Celgene and Novartis and a congress fee from Celgene. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Centre Nijmegen, The Netherlands. LJ van Vugt carried out clinical trials for AbbVie, Celgene, Janssen and Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Centre Nijmegen, The Netherlands. LMD Vandermaesen has no conflicts to declare. JMPA van den Reek carries out clinical trials for AbbVie, Celgene and Janssen; has received speaker’s fees/attended advisory boards for AbbVie, BMS and Janssen and has received reimbursement for attending a symposium from Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Centre Nijmegen, The Netherlands. EMGJ de Jong has received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Centre Nijmegen, The Netherlands from AbbVie, Pfizer, Novartis, Janssen Pharmaceuticals and Leo Pharma, and has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including AbbVie, Janssen, Novartis, Lily, Celgene, Leo Pharma, UCB and Almirall. All funding is not personal but goes to the independent research fund of the department of Department of Dermatology of the Radboud University Medical Centre Nijmegen, The Netherlands.
: Ethics approval was not required as the study was not subject to the Medical Research Involving Human Subjects Act (WMO). All patients who agreed to start dose tapering had been included in the prospective BioCAPTURE registry, and therefore provided written informed consent to use their clinical data for scientific purposes.
: All patients provided verbal informed consent.
: Not applicable.
: All data generated or analysed during this study are included in this published article and its Supplementary Information files.
: All statistical analyses were performed using SPSS (Version 25.0. Armonk, NY: IBM Corp).
: All authors contributed to the study conception and design. Material preparation and data collection was performed by MEM, SA, LJV and LMDV. Analyses were performed by MEM and SA. Supervision was performed by JMPAR and EMGJJ. The first draft of the manuscript was written by MEM and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.